Robert Henry, MD, from the University of California, San Diego discusses dual PPAR agonists and their potential for the treatment of type 2 diabetes and its cardiovascular comorbidities. Provided by the Institute for Diabetes, Obesity, and Cardiovascular Disease (iDOC), a free resource for continuing medical education and other tools for medical professionals focused on the treatment of these three related conditions. Visit www.idoc.org for more information.
Video Rating: 5 / 5



